Background. Interleukin 22 (IL-22) is emerging as a key cytokine for gut epithelial homeostasis and mucosal repair. Gut disruption is a hallmark of human immunodeficiency virus (HIV) infection. Here, we investigated IL-22 production and gut mucosal integrity in HIV type 1 (HIV-1)-infected individuals receiving long-term antiretroviral therapy (ART).
emerged as a key cytokine in these processes [2] . Signaling via the IL-22 receptor induces proliferative and antiapoptotic molecules in gut epithelial cells [3] , which have been shown to be critical for epithelial homeostasis, particularly in the context of mucosal insults. Additionally, IL-22 signaling triggers epithelial production of antimicrobial peptides, which are relevant both for the containment of the gut microflora and the response to infections [4] .
While the IL-22 receptor is essentially expressed by nonhematopoietic cells, specifically the gut epithelia, IL-22 itself is produced, under tight regulation, by hematopoietic cells [2] . Of note, high rates of epithelial proliferation due to deregulated IL-22 production have been associated with colon cancer [5] . In the context of epithelial lesions, shedding of microbial products leads to the secretion of interleukin 23 by dendritic cells [6] , which, in conjunction with interleukin 1β and interleukin 6, induces IL-22 production. On the other hand, interleukin 25 secretion by the intact/repaired epithelium is known to inhibit this process [7] .
The main IL-22 producers in the gut mucosa are CD4 + T cells (T-helper type 22 [Th22] cells) [8] and a subset of innate lymphoid cells (ILCs), named ILC3 [9] . It is currently unknown whether factors governing IL-22 production impact distinctly on the above 2 populations or whether these populations differentially contribute to the preservation of mucosal integrity [10] . ILC3 were initially described as participating in the development of gut-associated lymphoid tissue (GALT) [11] and were later shown to be critical for the response to tissue injury in adult life in the gut, thymus, and lymph nodes [12, 13] . In addition to their nonredundant contribution to the control of attaching-effacing enteric infections [14] , ILC3 were recently reported to suppress CD4 + T-cell activation in response to commensal bacteria [15] , further emphasizing their fundamental role in intestinal homeostasis. IL-22 is likely to be implicated in the pathogenesis of human immunodeficiency virus (HIV) infection and AIDS, given the profound disruption of gut mucosa typically observed throughout disease [16] . Acute HIV type 1 (HIV-1) infection leads to a massive loss of mucosal CD4 + T cells, which persists into the chronic phase [17] , and is inconsistently recovered upon longterm antiretroviral therapy (ART) [18] . Loss of epithelial integrity and high levels of circulating microbial products have been reported even in treated patients and are considered important contributors to HIV-associated pan-immune activation that underlies the pathogenesis of HIV infection and AIDS [19] [20] [21] .
The heightened activation state of the immune system is also associated with an increased risk of noninfectious events in ART-treated individuals. Most previous studies of the gut of HIV-1-infected patients focused on the loss of IL-17-producing cells [22] . However, given the overlap between the mucosal populations that produce IL-22 and/or interleukin 17 [10] , it is possible that some of the reported disturbances were due to IL-22. Interestingly, although IL-22 was initially described as a Th17 cytokine, there are several factors supporting a unique identity for IL-22-producing cells [8, 10] . Production of these 2 cytokines is linked to expression of the transcriptional factor retinoic acid orphan receptor (ROR)γt and the homing receptor CCR6 [23] . However, aryl hydrocarbon receptor (AHR) ligands have a preferential impact on IL-22 production [24] . Additionally, transforming growth factor β (TGF-β) induces IL-17 secretion while inhibiting IL-22 production via c-Maf induction in CD4 + T cells [25] . Nevertheless, concomitant production of IL-17 may balance positive and negative impacts of IL-22, as suggested in inflammatory bowel disease [26] . The limited data available suggest that mucosal IL-22 production is reduced during chronic HIV-1 [27] and simian immunodeficiency virus (SIV) infections [28] . However, mucosal distribution of enteric IL-22-producing cell populations in humans is still poorly defined. Furthermore, their relationship with the expression of genes involved in epithelial structure homeostasis is yet to be determined.
We performed a comprehensive study of Th22 cells and ILC3 in the sigmoid mucosa of long-term-treated HIV-1-infected individuals with effective control of viremia and immune reconstitution. We found histological evidence of mucosal integrity, despite a significant depletion of IL-22-producing CD4 + T-cells, compared with findings for HIV-1-seronegative subjects. Strikingly, our study revealed preserved numbers of ILCs and normal levels of mucosal IL-22-induced molecules. Thus, our data indicate a dissociation of the mechanisms that maintain Th22 and ILC3 in the human gut, highlighting ILC3 as potentially important therapeutic targets in achieving mucosal integrity in HIV.
METHODS

Studied Cohorts
The study enrolled 37 individuals with a clinical indication to perform colonoscopy (35 of 37 were for colon cancer screening) who were found to be cancer free: 17 were HIV-1-infected individuals who had been receiving ART for a median duration of 8 years with evidence of effective virological and immunological response, and 20 were HIV-1-seronegative patients (Table 1 ). All individuals gave written informed consent for blood sample and gut biopsy specimen collection and processing. The study was conducted under the approval of the Ethical Boards of the Faculty of Medicine of University of Lisbon, Hospitals Santa Maria and São Bernardo.
Cell Isolation and Culture
Twelve sigmoid biopsy specimens per individual were collected from macroscopically normal mucosa and processed immediately. A total of 7-10 biopsy specimens were digested with collagenase B (10 mg/mL, Roche, Penzberg, Germany) at 37°C and were then mechanically macerated. Lymphocytes were separated by Percoll gradient and cultured for 16 hours at 37°C in complete medium [29] . Cytokine production was assessed after 4-hour stimulation with phorbol myristate acetate plus ionomycin, as previously described [29] . Blood specimens were collected in parallel from 10 HIV-1-infected and 9 control individuals, and peripheral blood mononuclear cells (PBMCs) were isolated by a Ficoll-Hypaque centrifugation gradient.
Flow Cytometry
Cells were surface and intracellularly stained (Foxp3 Staining Buffer Set, Ebioscience) as previously described [30] , using a panel of antibodies (Supplementary Figure 1) . Circulating lymphocyte populations were characterized using whole-blood staining and were analyzed for activation markers as previously described [31, 32] . The following antibody combinations were used to identify mucosal ILC and T-cell subsets: IL-17/IL-22/cKIT/ IFN-γ/NKp44/LD/CD45/CD3 and IL-17/IL-22/CD8/IFN-γ/ CD4/LD/FOXP3/CD3, respectively. Cytokine production by PBMCs was quantified using CCR7/IL-22/IL-17/IFN-γ/CD8/ CD45RO/IL-2/CD3 within memory-effector T cells. Unstimulated cells were used to define cytokine cutoffs.
Immunohistochemistry Staining
One sigmoid biopsy specimen and 1 ileum biopsy specimen were embedded in paraffin after preservation in 4% formaldehyde. Three-micrometer sections were stained with antibodies (Supplementary Table 1 ) after paraffin removal with xylene, rehydration with alcohol, and antigen retrieval by heat. Cells were counted manually in 10 images (original magnification ×400) acquired with a Leica DM2500 bright-field microscope, and the lamina propria area was assessed using ImageJ 1.47i (National Institutes of Health, Bethesda, MD) in blinded samples by 2 researchers. Staining with hematoxylin-eosin, Masson's trichrome, and periodic acid Schiff-Alcian blue (PAS-AB) was concurrently performed, and stained specimens were blindly evaluated by a trained pathologist. Samples were scored according to inflammatory alterations, type of infiltrate, presence or absence of fibrosis, and number of mitotic figures at the crypt base, with scores ranging from 0 to 3.
Immunofluorescence Staining
One sigmoid biopsy specimen and 1 ileum biopsy specimen were frozen in OCT (VWR, Radnor, PA) after 6-hour preservation in 4% paraformaldehyde, followed by 24 hours in 18% sucrose to preserve biopsy structure. Three-micrometer tissue sections were stained by sequential antibody incubations (Supplementary Table 1 ) after protein blocking. DAPI was used for nuclear counterstaining. Images were acquired with a Zeiss LSM 710 confocal microscope (Carl Zeiss, Oberkochen, Germany), using a Plan-Apochromat 20×/0.8 objective; the surface area was measured with ImageJ 1.47i; and positive cells were counted using in-house software, written in MATLAB (Mathworks, Natick, MA), allowing automatic generation of individual report images for cell-counting verification ( Figure 1 ). 
RNA Extraction and Analysis
One sigmoid biopsy specimen and 1 ileum biopsy specimen were stored in RLT buffer (Qiagen, Valencia, CA) immediately after collection. RNA was extracted using the Allprep RNA/ DNA mini kit (Qiagen), and 250 ng was used to synthesize complementary DNA (SuperScript III, Life Technologies). Expression levels of IL22, IL17A, IL22RA1, IL23, IL23R, IL25, TGFB1, IL1B, IL6, MUC1, MUC13, S100A9, REG3G, DEFB4A, AHR, and IDO1 were measured after preamplification with the TaqMan Preamp Master Mix, using TaqMan gene expression assays with an Applied Biosystems 7500 Fast Real-Time PCR System (all from Life Technologies). Results are expressed as ΔCT normalized to the medium CT levels of GAPDH and r18S. When gene expression was undetectable, a CT value of 40 was used for statistical analysis.
Statistical Analysis
Results are expressed as medians and interquartile ranges (IQRs). Comparisons between 2 groups were made using Mann-Whitney U test, using Graph Prism, version 5.0 (GraphPad Software, San Diego, CA). Nonadjusted regression analysis or Spearman correlation was used to identify associations between several parameters, and multivariate linear regression analysis was used to adjust results for age or sex, using Stata, version 12.1 (StataCorp, College Station, TX). Analysis and presentation of distributions of IL-22-producing cells was performed using SPICE, version 5.1 (available at: http://exon. niaid.nih.gov). Comparison of cytokine-producing subset distributions was performed using the Wilcoxon signed rank test and partial permutation test [33] . P values of <.05 were considered statistically significant.
RESULTS
IL-22-Producing Cells in the Sigmoid Mucosa
Mucosal IL-22 production was evaluated in sigmoid biopsies from 17 long-term-treated HIV-1-infected individuals with effective suppression of viremia and evidence of immunological reconstitution and 20 HIV-1-seronegative patients ( Table 1) . The total amount of IL-22 production in the sigmoid mucosa was quantified within hematopoietic cells, defined as CD45 CD3 + cells that express IL-22 were counted using a program developed in-house. Briefly, single-cell nuclei were identified via DAPI by thresholding and particle analysis, and dilated regions of interest (ROIs), based on a user-defined radius, were defined from each nuclei as the corresponding cellular areas for the other 3 channels. For each channel and ROI, a staining was considered positive if a minimum number of pixels (usually 5) were above a given threshold, and a particular combinatorial filter for cell counting was defined on the basis of staining (eg, positive staining in channels A and B but not channel C or positive staining in channels B and C regardless of staining in channel A). Cell numbers are shown in blue. B, Number of IL-22
+ cells/mm 2 in HIV-1 (n = 16) and seronegative (n = 13) cohorts. Each dot represents 1 individual, and bars represent medians. Groups were compared using Mann-Whitney U test. P values are shown.
revealed Figure 2) . Our data are in line with previous studies demonstrating a distinct impact of HIV-1 infection of the colon and ileum [34] . Overall, both the frequency and total numbers of IL-22-producing cells were significantly reduced in the sigmoid mucosa in HIV-1 infection even after long-term ART.
Mucosal Th22 Cells
The immunofluorescence staining of IL-22 and CD3 showed a significant depletion of IL-22-producing T cells in HIV-1-positive patients as compared to HIV-1-seronegative subjects (Figure 1 ).
CD4
+ T cells were shown to be the main producers of IL-22
in the human gut [2] . Our analysis of cell suspensions confirmed that adaptive IL-22 production was mostly restricted to mucosal CD4 + T cells, although some subjects (5 of 15 HIV-1-infected individuals and 4 of 13 controls) featured a few IL-22-producing CD8 + T cells (<2.5% of the CD8 + T-cell population; Supplementary Figure 1) . We found that the frequency of IL-22-producing cells within the CD4 + T-cell subset was significantly decreased in treated HIV-1-positive individuals (Figure 2A and 2B) , even after adjustment for the total number of mucosal CD4 + T cells (R = −5.9; P = .008).
Of note, our long-term-treated HIV-1-infected cohort showed no significant reduction of CD4 + T-cell counts in the Figure 1) . The levels of mucosal Th22 cells were not related to peripheral blood CD4 + T-cell counts (R = −0.031; P = .89; n = 22) or to the frequency of circulating IL-22-producing CD4 + T cells (R = 0.1; P = .72; n = 17), with the latter values being similar in the HIV-1-infected and control cohorts (Table 1) . Importantly, there was no association between mucosal Th22 frequency and nadir CD4 + T-cell count before ART or by length of therapy.
Interestingly, aging was associated with a progressive increase in IL-22-producing cells within mucosal CD4 + T cells in healthy subjects ( Figure 2C ). This relationship was not observed in the HIV-1-infected cohort ( Figure 2C ), supporting a disturbed homeostasis of this subset in the sigmoid mucosa, even after long-term receipt of ART. Nevertheless, the proportion of Th22 cells that concomitantly produce IL-17 and/or IFN-γ revealed no significant imbalances in HIV-1-infected patients as compared to healthy individuals ( Figure 2D) , with all IL-22-producing CD4 + T-cell subsets underrepresented in the HIV-1-infected cohort (Supplementary Figure 1) . Mucosal Th22 cells had significantly more coexpression of IL-17 and/or IFN-γ than the circulating counterparts in both cohorts (data not shown). Thus, despite the major Th22 cell depletion found in HIV-1-infected patients, the factors governing the balance of these Th22 cell subpopulations seemed to be operating as in controls.
The frequency of the other main CD4 + T-cell subsets, namely ; n = 17]; P = .89).
In conclusion, long-term-treated HIV-1-infected individuals exhibited a significant depletion of Th22 cells in the sigmoid mucosa.
Levels of Molecules Known to Regulate IL-22 Production in the Sigmoid Mucosa
Next, we investigated possible alterations in the expression levels of molecules known to modulate IL-22 production in the gut. We found no alterations in the mRNA expression levels of IL23, IL23R, IL6, IL1B, AHR, IL25, IDO1, and TGFB1 (Figure 3) . Moreover, the levels of these transcripts were not significantly associated with the frequency of IL-22-producing cells, either within total hematopoietic cells or CD4 + T cells (P > .3). Similar findings were obtained in ileum biopsies (Supplementary Figure 2 ).
Thus, the expression levels of the main regulators of mucosal IL-22 production were preserved in treated HIV-1-positive individuals, suggesting they feature a normal IL-22-permissive environment.
IL-22-Producing Non-T Cells and ILC3 in the Sigmoid Mucosa
Next we investigated IL-22 production by non-T cells, and found that it was comparable in the 2 cohorts ( Figure 4A ). Notably, HIV-1-infected and control individuals featured a similar profile of concomitant production of IL-17 and/or IFN-γ by non-T cells, with a marked prevalence of cells producing only IL-22 in both cohorts.
Additionally, we performed a triple immunofluorescence staining for CD3, RORγt, and IL-22 in the sigmoid mucosa and confirmed that the numbers of CD3 − RORγt + cells and CD3 − RORγt + IL-22 + cells were similar in the 2 cohorts ( Figure 4B ). The main source of innate IL-22 in the gut is a subset of ILCs that express the natural cytotoxic receptor NKp44: ILC3. HIV-1-infected individuals showed a preserved frequency of mucosal ILC3 cells, defined by the expression of cKIT and NKp44 within CD3
− cells, as compared to HIV-1-seronegative patients ( Figure 5A ). These cells expressed RORγt ( Figure 5B ), which is essential for their development and function [35] . Moreover, similar to healthy subjects, the mucosal ILCs of HIV-1-positive individuals also expressed high levels of the IL-7 and interleukin 2 receptor α chains (CD127 and CD25, respectively; Supplementary Figure 1 ) [36] . In agreement with previous data [37] , we found that the ILC3 subset was the main producer of Figure 3 . Levels of expression of genes known to modulate interleukin 22 (IL-22) production and/or function. IL23, IL25, AHR, IDO1, TGFB1, IL6, IL1B, IL23R, and IL22RA1 messenger RNA levels in total RNA extracted from sigmoid biopsy specimens of human immunodeficiency virus type 1 (HIV-1)-infected and seronegative individuals. Numbers below indicate the total number of samples tested and those with levels above the detection threshold of the respective gene. Results are expressed in relative units, normalized to the mean CT levels of GAPDH and r18S. Bars represent medians and interquartile ranges. Comparisons were made using the Mann-Whitney U test. P values are shown, supporting the lack of any significant differences.
IL-22 in both healthy and HIV-1-infected individuals, with no skewing toward IFN-γ production ( Figure 5B ). Of note, a multivariate regression analysis including HIV status and sex as cofactors confirmed that sex did not bias our results regarding the frequencies of ILC (P = .42), IL-22-producing non-T cells (P = .49), or CD4 + T cells (P = .18).
Hence, in contrast to Th22 cell depletion, treated HIV-1-infected patients featured a preserved frequency of innate IL-22-producing cells.
Epithelial Preservation in Long-Term-Treated HIV-1-Positive Individuals
Finally, we investigated the degree of sigmoid epithelial disruption in the context of marked Th22 cell depletion but preserved ILC3.
Initially, we quantified expression of IL-22-target genes, which are likely to help maintain epithelial integrity. We found that the genes for mucins (MUC1 and MUC13) and antimicrobial peptides (REG3G, S100A9, and DEFB4A) were similarly expressed in the HIV-1-infected and control cohorts ( Figure 6A ). The strong association we observed between the levels of transcripts for IL22RA1 and MUC13 ( Figure 6B ) is worth emphasizing, as it supports the role of IL-22 in the induction of this particular molecule. Ileum biopsy specimens from both cohorts also featured similar levels of these transcripts (Supplementary Figure 2) . Furthermore, there was no evidence of compromised tight junction integrity, as assessed by levels of expression of zonula occludens 1 (ZO-1; Figure 6C ).
Additionally, blinded examination of specimens stained with hematoxylin-eosin, Masson's trichrome, and PAS-AB revealed no significant differences between the 2 cohorts with respect to crypt morphology, number and type of cell infiltrates, and number of epithelial mitotic events ( Figure 6D ). Mucin production was apparently preserved in all samples, and significant collagen deposition was only found in biopsy specimens from 2 HIV-1-infected individuals (data not shown).
Interestingly, our long-term-treated HIV-1-infected cohort showed no significant increase in the expression of activation markers in circulating CD4 + and CD8 + T-cell subsets or an expansion of CD16 + cells within CD14 bright monocytes (Table 1 ).
The lack of upregulation of these markers, which have been associated with microbial translocation, was in agreement with preserved epithelial integrity, as suggested by our histological data and the levels of antimicrobial peptides. Altogether, our study of long-term-treated HIV-1 infection provides evidence for full epithelium integrity in the context of significant Th22 cell depletion and preserved ILC3.
DISCUSSION
Maintenance of intestinal homeostasis is linked to IL-22 production in the lamina propria [26] . This study provided evidence favoring distinct regulation of the 2 main IL-22 producers in the human gut, CD4 + T cells (Th22 cells) and ILC3.
We showed that IL-22-mediated processes were functioning in long-term-treated HIV-1-infected patients, despite evidence of Th22 cell depletion. Conversely, innate IL-22 production was unaltered, suggesting a role for ILC3 in ensuring epithelial integrity. Gut disruption is a hallmark of HIV-1 infection, and the restoration of intestinal integrity upon ART initiation is still controversial [18] . Using a comprehensive approach combining tissue structure analyses, cell counts, and relative proportion of functionally characterized populations, as well as quantification markers associated with microbial translocation, in our long-term-treated HIV-1-infected cohort. Importantly, our study revealed the maintenance of several processes that are known to rely on IL-22, namely ZO-1-associated tight junction integrity and production of regulins, S100, defensins, and mucins, all of which are essential for preserving intestinal homeostasis [38] . This central role of IL-22 in tissue repair is in line with several reports in other clinical contexts and models of disease [26] .
Strikingly, we documented mucosal integrity despite the significant Th22 cell depletion in the sigmoid mucosa of longterm-treated HIV-1-infected individuals. To our knowledge, there is only 1 report that evaluated IL-22 production in the human sigmoid mucosa [27] . This cross-sectional study described Th22 cell depletion associated with disruption of epithelial integrity that was apparently recovered in treated patients. However, this recovery should be cautiously interpreted because only 8, much younger controls were evaluated. This is particularly critical given our finding of a positive correlation between the frequency of Th22 cells among CD4 + T cells and age in HIV-1-seronegative subjects. Thus, the use of a large cohort of age-matched controls strengthens our observation of Th22 cell depletion after long-term ART in HIV-1 infection. This preferential Th22 cell depletion could not be linked to an altered expression of factors that distinctly govern IL-22 and IL-17 production, namely AHR [24] and TGF-β [25] . The possibility of distinct homing requirements should be explored in future studies.
Interestingly, irrespective of HIV-1 infection status of the subjects, our parallel study of circulating and mucosal Th22 cells revealed higher coproduction of IL-17 and/or IFN-γ in the latter group. It is plausible that cytokine patterns are influenced by the mucosal environment, in which case the similarity of the Th22 profile in the 2 cohorts represents an additional argument in favor of gut integrity in long-term-treated HIV-1-infected patients. In agreement, no skewing toward IFN-γ production was found in ILC3 of the HIV-1 cohort, in contrast with published data on untreated SIV infection in nonhuman primates [39] .
Importantly, ILC3 were not depleted in the treated HIV-1 cohort, supporting a role for distinct factors governing the homeostasis of the 2 main IL-22-producing subsets in the gut mucosa. Given the lower frequency of these cells and the limited amount of tissue obtained during human studies, data on the relative contribution of ILC3 and Th22 cells to IL-22 production are still scarce. In contrast, murine models of colitis have generated data in favor of distinct regulation of these 2 subsets during disease [40] . Moreover, ILCs were shown to maintain epithelial preservation in the absence of IL-22 production by T cells [40] . Thus, it is plausible that the relative proximity to epithelial cells, rather than the actual frequency in lamina propria, may determine the role played by ILCs in maintaining epithelial integrity and may also help preserve epithelial stem cells [3] . Nevertheless, although we were able to identify ILC3 in the human gut, the structure of the frozen tissue biopsy specimens was insufficiently preserved to allow us to assess their relative localization in relation to Th22 cells. Notably, in addition to IL-22 production, ILC3 were recently reported to control mucosal inflammation by modulating local CD4 + T-cell activation [15] . Thus, ILC3 may represent an important population to target in the context of HIV-1 infection, since a hyperactivated state is believed to underlie mucosal damage. Overall, mucosal homeostasis, including IL-22-mediated mechanisms essential for epithelial integrity, could mainly rely on ILCs, as suggested by our data on long-term-treated HIV-1-infected patients. Thus, the therapeutic targeting of ILCs may represent an important strategy to promote intestinal recovery.
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